Earnings History Data for Takeda Pharmaceutical Company Limited (TAK) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, J...

Release Date	Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
31-10-2024	PM	TAK	Takeda Pharmaceutical Company Limited	43,460	0.44	0.39	0.50	Takeda Pharmaceutical reports H1 results, revises FY forecast [10/31/2024 2:15 AM]	13.93	0.04 (0.29%)	13.96	0.07 (0.50%)	12.57 - 15.08	1,025,112	1,380,000	6,757
Takeda Pharmaceutical reports H1 results, revises FY forecast [10/31/2024 2:15 AM] Takeda Pharmaceutical FQ2 Earnings Preview [10/30/2024 11:16 AM] HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda [2024-10-31 04:30AM] Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook [2024-10-31 02:05AM] What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings [Oct-30-24 09:00AM]
31-07-2024	PM	TAK	Takeda Pharmaceutical Company Limited	42,990	0.56	0.37	0.55	Takeda Pharmaceutical Non-GAAP EPS of ¥176.00, revenue of ¥1208B; reaffirms FY24 outlook [7/31/2024 2:50 AM]	13.90	0.25 (1.83%)	13.65	0.0 (0.00%)	12.57 - 16.39	3,945,092	3,170,000	135,215
Takeda Pharmaceutical Non-GAAP EPS of ¥176.00, revenue of ¥1208B; reaffirms FY24 outlook [7/31/2024 2:50 AM] Takeda Pharmaceutical Q1 Earnings Preview [7/30/2024 12:41 PM]
09-05-2024	PM	TAK	Takeda Pharmaceutical Company Limited	41,670	N/A	0.00	0.39	Takeda Pharmaceutical Non-GAAP EPS of ¥484, revenue of ¥4263.8B; initiates FY24 outlook [5/9/2024 2:15 AM]	13.37	0.30 (2.34%)	12.90	-0.16 (-1.23%)	12.77 - 17.11	2,787,726	1,370,000	22,969
Takeda seeks efficiency as operating profit slumps [5/9/2024 8:29 AM] Takeda Pharmaceutical Non-GAAP EPS of ¥484, revenue of ¥4263.8B; initiates FY24 outlook [5/9/2024 2:15 AM] Takeda Pharmaceutical Q4 Earnings Preview [5/8/2024 2:10 PM]
01-02-2024	PM	TAK	Takeda Pharmaceutical Company Limited	46,340	0.51	0.00	0.46	Takeda Pharmaceutical GAAP EPS of ¥94.00, revenue of ¥3212.9B; reaffirms FY23 guidance [2/1/2024 1:21 AM]	14.39	-0.21 (-1.44%)	14.67	0.07 (0.48%)	13.19 - 17.15	3,286,572	1,660,000	9,696
Takeda Pharmaceutical gets new CFO [2/1/2024 2:26 AM] Takeda Pharmaceutical GAAP EPS of ¥94.00, revenue of ¥3212.9B; reaffirms FY23 guidance [2/1/2024 1:21 AM] Protagonist Therapeutics stock rises on Takeda license deal [2/1/2024 9:12 AM]
26-10-2023	PM	TAK	Takeda Pharmaceutical Company Limited	45,210	0.50	0.00	0.52		13.39	-1.11 (-7.62%)	13.88	-0.62 (-4.28%)	12.89 - 17.15	8,415,719	1,500,000	16,133
Takeda Pharmaceutical gives H1 results, raised FY guidance [10/26/2023 2:26 AM]
11-05-2023	PM	TAK	Takeda Pharmaceutical Company Limited	53,150	0.39	0.00	0.38	Takeda Pharmaceutical Non-GAAP EPS of ¥558.00, revenue of ¥4.03B; initiates FY23 guidance [5/11/2023 3:31 AM]	16.16	-0.82 (-4.80%)	16.64	-0.34 (-2.00%)	12.28 - 17.15	5,513,151	1,950,000	6,766
Takeda Pharmaceutical Non-GAAP EPS of ¥558.00, revenue of ¥4.03B; initiates FY23 guidance [5/11/2023 3:31 AM] Takeda FY22 sales grow but FY23 outlook weighed down by generic impact [5/11/2023 7:05 AM]
28-07-2022	PM	TAK	Takeda Pharmaceutical Company Limited	45,370	0.56	0.00	0.51	Takeda Pharmaceutical Non-GAAP EPS of ¥145.00, revenue of ¥972.5B, maintains FY guidance [7/28/2022 2:14 AM]	14.81	0.13 (0.85%)	14.71	0.02 (0.14%)	13.05 - 17.31	2,211,701	3,030,000	22,259
Takeda Q1 sales rise on gastro business; maintains FY22 outlook; pulls Exkivity filing in EU [7/28/2022 8:26 AM] Takeda Pharmaceutical Non-GAAP EPS of ¥145.00, revenue of ¥972.5B, maintains FY guidance [7/28/2022 2:14 AM] Dr. Reddy's launches generic of Takeda's cancer drug Velcade in US [7/27/2022 5:39 AM] Takeda maintains annual guidance despite first-quarter profit drop [Jul-28-22 02:44AM] UPDATE 2-Takeda maintains annual guidance despite first-quarter profit drop [Jul-28-22 02:42AM] Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance [Jul-28-22 02:00AM] EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets [Jul-27-22 06:45AM]
11-05-2022	PM	TAK	Takeda Pharmaceutical Company Limited	45,400	0.38	0.00	0.41	Takeda Pharmaceutical GAAP EPS of ¥425.00, revenue of ¥3.42T [5/11/2022 2:26 AM]	13.95	-0.57 (-3.93%)	14.11	-0.41 (-2.82%)	13.17 - 17.56	2,213,744	2,560,000	2,643
Takeda Pharmaceutical GAAP EPS of ¥425.00, revenue of ¥3.42T [5/11/2022 2:26 AM] Takeda's FY21 revenue gets boost from gastro dug Entyvio sales; provides FY22 outlook [5/11/2022 6:53 AM] Japan's Takeda forecasts rebound despite full-year profit drop [May-11-22 02:20AM] Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022 [May-11-22 02:15AM]
28-10-2021	PM	TAK	Takeda Pharmaceutical Company Limited	43,460	0.45	0.00	0.47		14.11	0.29 (2.10%)	14.15	0.33 (2.39%)	13.80 - 19.96	4,258,324	2,190,000	59,601
Takeda Pharmaceutical sees operating profit surge in H1 2021 [10/28/2021 11:49 AM] Takeda Pharmaceutical reports 1H results, announces buyback [10/28/2021 2:12 AM] Takeda Pharmaceutical FQ2 Earnings Preview [10/27/2021 1:05 PM] Takeda exercises option to acquire immunotherapy-focused GammaDelta Therapeutics [10/27/2021 9:24 AM] The Petri Dish: Selecta, Takeda ink $1.1B deal; Moderna ups Africa commitment [Oct-28-21 06:30AM] Takeda Announces Acquisition of Own Shares [Oct-28-21 03:01AM] Japan's Takeda announces share buyback as profit climbs [Oct-28-21 02:46AM] Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands [Oct-28-21 02:15AM] Closing Gaps and Restoring Trust: Building on UNGA76 to Strengthen Global Health Systems [Oct-27-21 01:16PM] Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout [Oct-27-21 12:03PM] Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic T Cell Therapies Addressing Solid Tumors [Oct-27-21 09:15AM] Novavax files for its first COVID-19 vaccine authorization in UK [Oct-27-21 08:48AM] BioLife Plasma goes green in Tukwila with first all-electric donation center [Oct-27-21 01:18AM]
31-07-2020	PM	TAK	Takeda Pharmaceutical Company Limited	56,950	0.57	0.00	0.56	Takeda Pharmaceutical misses on revenue [7/31/2020 4:28 AM]	18.16	0.0 (-0.01%)	18.42	0.26 (1.43%)	12.43 - 20.92	425,349	1,162,062	7,344